RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-kappa B-mediated epithelial-mesenchymal transition

RUFY3 (RUN and FYVE domain-containing protein 3) has been demonstrated to exhibit carcinogenic effect in multiple malignancies. However, the exact role of RUFY3 in hepatocellular carcinoma (HCC) progression remains elusive. Herein, we aimed to identify the role and the underlying mechanism of RUFY3 in HCC progression. The RUFY3 levels in HCC specimens were detected by qRT-PCR, western blot, and immunohistochemistry, and its clinical significance in HCC patients was assessed. The effect of RUFY3 on HCC cell growth, migration, and invasion was explored by CCK-8 assay, wound healing assay, and transwell migration and invasion assays in vitro. The effect of RUFY3 on HCC cell growth and metastasis was also conducted in vivo through establishing xenograft tumor and lung metastatic mice model. The underlying mechanism responsible for RUFY3-induced HCC cell behavior was also investigated. Our results indicated that high levels of RUFY3 significantly correlated with tumor size, microvascular invasion, clinical stage, and poor prognosis for HCC patients. In addition, RUFY3 facilitated HCC cell growth, invasion, and metastasis both in vitro and in vivo through activating nuclear factor-kappa-gene binding (NF-kappa B)-mediated epithelial-mesenchymal transition (EMT). Taken together, our results revealed that RUFY3 accelerated HCC progression via driving NF kappa B-mediated EMT, suggesting a novel target for HCC treatment.

Automated summary

In this study, the researchers aimed to investigate the role and mechanism of RUFY3 in hepatocellular carcinoma (HCC) progression. Results showed that high expression of RUFY3 was significantly associated with tumor size, microvascular invasion, clinical stage, and poor prognosis in HCC patients. Furthermore, RUFY3 was found to promote HCC cell growth, invasion, and metastasis through activating NF-kappa B-mediated epithelial-mesenchymal transition (EMT). These findings suggest that RUFY3 may serve as a novel target for HCC treatment.